Clinical TrialJul 1, 2026, 07:01 AM
Can-Fite Namodenoson Phase 2a Pancreatic Cancer Study Meets Safety
AI Summary
Can-Fite BioPharma announced positive results from its Phase 2a study of Namodenoson in advanced pancreatic ductal adenocarcinoma. The study met its primary safety endpoint and demonstrated durable overall survival outcomes, with a median overall survival exceeding 5 months in evaluable third-line patients. Notably, one second-line patient remains alive for over 18 months. Based on these findings, Can-Fite plans to advance Namodenoson into a Phase 2b combination study with chemotherapy.
Key Highlights
- Namodenoson Phase 2a study met primary safety endpoint in pancreatic cancer.
- Durable overall survival outcomes observed in advanced pancreatic ductal adenocarcinoma patients.
- Median overall survival exceeded 5 months in evaluable third-line patients.
- 62.5% of evaluable third-line patients survived five months or longer.
- One second-line patient remains alive over 18 months after treatment initiation.
- Can-Fite plans to advance Namodenoson into a Phase 2b combination study with chemotherapy.
Price Impact
More from CANF